Arcturus Therapeutics Holdings Inc. (ARCT) Income Statement Analysis

See more : Compagnie Financière Richemont SA (CFRHF) Income Statement Analysis – Financial Results

Complete financial analysis of Arcturus Therapeutics Holdings Inc. (ARCT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arcturus Therapeutics Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Arcturus Therapeutics Holdings Inc. (ARCT)

Industry: Biotechnology

Sector: Healthcare

Website: https://arcturusrx.com

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	157.75M	205.76M	12.36M	9.54M	20.79M	15.75M	13.00M	20.38M	6.14M	0.00	0.00	0.00	0.00
Cost of Revenue	2.96M	143.05M	171.86M	55.95M	32.44M	16.98M	410.00K	294.00K	51.00K	0.00	0.00	0.00	0.00
Gross Profit	154.79M	62.70M	-159.50M	-46.41M	-11.65M	-1.23M	12.59M	20.09M	6.09M	0.00	0.00	0.00	0.00
Gross Profit Ratio	98.13%	30.48%	-1,290.57%	-486.50%	-56.04%	-7.80%	96.85%	98.56%	99.17%	0.00%	0.00%	0.00%	0.00%
Research & Development	192.13M	147.75M	173.76M	57.85M	33.64M	16.98M	15.92M	18.39M	13.46M	25.11M	7.07M	818.00K	1.82M
General & Administrative	52.87M	46.07M	41.45M	23.22M	12.66M	20.58M	7.57M	5.36M	4.99M	5.84M	3.22M	683.00K	2.08M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	52.87M	46.07M	41.45M	23.22M	12.66M	20.58M	7.57M	5.36M	4.99M	5.84M	3.22M	683.00K	2.08M
Other Expenses	0.00	-244.00K	0.00	0.00	0.00	0.00	-348.00K	1.42M	1.25M	2.13M	0.00	0.00	0.00
Operating Expenses	235.95M	193.58M	215.21M	81.06M	46.30M	37.56M	23.49M	25.17M	19.70M	33.08M	10.29M	1.50M	3.91M
Cost & Expenses	245.00M	193.58M	215.21M	81.06M	46.30M	37.56M	23.49M	25.17M	19.70M	33.08M	10.29M	1.50M	3.91M
Interest Income	17.36M	2.58M	753.00K	470.00K	408.00K	514.00K	89.00K	798.00K	338.00K	239.00K	22.00K	2.00K	21.00K
Interest Expense	767.00K	420.00K	2.67M	361.00K	446.00K	186.00K	150.00K	295.00K	251.00K	2.00K	197.00K	80.00K	44.00K
Depreciation & Amortization	2.96M	1.53M	1.19M	882.00K	684.00K	582.00K	410.00K	294.00K	51.00K	31.00K	8.00K	7.00K	6.00K
EBITDA	-24.17M	13.70M	-201.66M	-70.64M	-24.42M	-20.72M	-10.34M	-947.00K	-1.72M	-32.81M	-10.28M	-1.51M	-3.92M
EBITDA Ratio	-15.32%	5.67%	-1,621.42%	-752.56%	-122.88%	-133.42%	-79.56%	-123.18%	-320.09%	0.00%	0.00%	0.00%	0.00%
Operating Income	-78.21M	12.18M	-202.85M	-71.52M	-25.51M	-21.81M	-10.49M	-25.17M	-19.70M	-33.08M	-10.29M	-1.50M	-3.91M
Operating Income Ratio	-49.58%	5.92%	-1,641.33%	-749.81%	-122.72%	-138.46%	-80.72%	-123.48%	-320.92%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	50.32M	-1.53M	-822.00K	-624.00K	-478.00K	26.00K	-409.00K	-536.00K	11.00K	227.00K	-197.00K	-78.00K	-23.00K
Income Before Tax	-27.89M	10.64M	-203.67M	-72.15M	-25.99M	-21.79M	-10.90M	-24.53M	-19.40M	-32.85M	-10.49M	-1.58M	-3.93M
Income Before Tax Ratio	-17.68%	5.17%	-1,647.98%	-756.35%	-125.02%	-138.29%	-83.87%	-120.35%	-316.03%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	1.84M	1.30M	3.19M	-784.00K	-270.00K	212.00K	1.00K	73.00K	51.00K	-17.00K	61.00K	65.00K	21.00K
Net Income	-29.73M	9.35M	-206.86M	-71.36M	-25.72M	-21.79M	-10.90M	-24.60M	-19.45M	-32.83M	-10.55M	-1.58M	-3.93M
Net Income Ratio	-18.84%	4.54%	-1,673.78%	-748.13%	-123.72%	-138.29%	-83.87%	-120.71%	-316.86%	0.00%	0.00%	0.00%	0.00%
EPS	-1.12	0.35	-7.86	-3.51	-2.13	-2.16	-3.53	-6.25	-6.29	-16.81	-7.25	-0.99	-2.47
EPS Diluted	-1.12	0.35	-7.86	-3.51	-2.13	-2.16	-3.53	-6.25	-6.29	-16.81	-7.25	-0.99	-2.47
Weighted Avg Shares Out	26.63M	26.45M	26.32M	20.31M	12.07M	10.07M	3.09M	3.94M	3.09M	1.95M	1.45M	1.59M	1.59M
Weighted Avg Shares Out (Dil)	26.63M	27.09M	26.32M	20.31M	12.07M	10.07M	3.09M	3.94M	3.09M	1.95M	1.45M	1.59M	1.59M

Arcturus Therapeutics to Attend Upcoming Investor Conferences

November 26, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company...

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

November 18, 2024businesswire.com

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

November 14, 2024seekingalpha.com

Interim results from phase 2 proof-of-concept study, using LUNAR-CF for treatment of patients with Cystic Fibrosis, expected 1st half of 2025. The global Cystic Fibrosis market size is projected to reach $62.57 billion by 2032. Interim results from phase 2...

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

November 14, 2024businesswire.com

TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment in ARCALIS, Inc. (Headquarters: Minami-soma City, Fukushima Prefecture; President: Satoshi Takamatsu; hereinafter...

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

November 11, 2024businesswire.com

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

November 7, 2024seekingalpha.com

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joseph Payne - President and CEO Andrew Sassine - CFO Pad Chivukula...